251 related articles for article (PubMed ID: 25524464)
1. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.
del Bufalo F; Carai A; Figà-Talamanca L; Pettorini B; Mallucci C; Giangaspero F; Antonelli M; Badiali M; Moi L; Bianco G; Cacchione A; Locatelli F; Ferretti E; Mastronuzzi A
J Transl Med; 2014 Dec; 12():356. PubMed ID: 25524464
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Dabrafenib for three children with brainstem BRAF
Philippe L; Maria K; Tariq A; Sofia M; Christine SM; Jean-Pierre F; Dudley RW; Sébastien P; Nada J; Valérie L
J Neurooncol; 2019 Oct; 145(1):135-141. PubMed ID: 31502039
[TBL] [Abstract][Full Text] [Related]
4. Pilocytic astrocytoma vs. ganglioglioma: Progression vs. misdiagnosis, and implications in BRAF testing.
Yoon J; Cusimano M; Munoz DG
J Clin Neurosci; 2019 Aug; 66():231-234. PubMed ID: 31147230
[TBL] [Abstract][Full Text] [Related]
5. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
Yau WH; Ameratunga M
J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
[TBL] [Abstract][Full Text] [Related]
6. Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib.
Aguilera D; Janss A; Mazewski C; Castellino RC; Schniederjan M; Hayes L; Brahma B; Fogelgren L; MacDonald TJ
Pediatr Blood Cancer; 2016 Mar; 63(3):541-3. PubMed ID: 26579623
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
8. Vemurafenib and cobimetinib overcome resistance to vemurafenib in
Touat M; Gratieux J; Condette Auliac S; Sejean K; Aldea S; Savatovsky J; Perkins G; Blons H; Ligon KL; Idbaih A; Hollebecque A; Gimenez-Roqueplo AP; Laurent-Puig P; Sanson M; Villa C; Di Stefano AL
Neurology; 2018 Sep; 91(11):523-525. PubMed ID: 30120137
[No Abstract] [Full Text] [Related]
9. Clinical relevance of BRAF status in glial and glioneuronal tumors: A systematic review.
Sugiura Y; Nagaishi M
J Clin Neurosci; 2019 Aug; 66():196-201. PubMed ID: 31147232
[TBL] [Abstract][Full Text] [Related]
10. Pilomyxoid astrocytoma treated successfully with vemurafenib.
Skrypek M; Foreman N; Guillaume D; Moertel C
Pediatr Blood Cancer; 2014 Nov; 61(11):2099-100. PubMed ID: 24821190
[TBL] [Abstract][Full Text] [Related]
11. Desmoplastic non-infantile astrocytoma/ganglioglioma: rare low-grade tumor with frequent BRAF V600E mutation.
Chatterjee D; Garg C; Singla N; Radotra BD
Hum Pathol; 2018 Oct; 80():186-191. PubMed ID: 29902580
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal mutational analysis of a cerebellar pilocytic astrocytoma recurring as a ganglioglioma.
Fiset PO; Fontebasso AM; De Jay N; Gayden T; Nikbakht H; Majewski J; Jabado N; Albrecht S
Pediatr Blood Cancer; 2017 Feb; 64(2):275-278. PubMed ID: 27718322
[TBL] [Abstract][Full Text] [Related]
13. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
[No Abstract] [Full Text] [Related]
15. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
Pasqualetti F; Restante G; Gonnelli A; Rofi E; Molinari A; Crucitta S; Paiar F; Rudà R; Danesi R; Soffietti R; Del Re M
Neuro Oncol; 2019 Dec; 21(12):1610-1611. PubMed ID: 31504796
[No Abstract] [Full Text] [Related]
16. KIAA1549:BRAF fusion gene in pediatric brain tumors of various histogenesis.
Antonelli M; Badiali M; Moi L; Buttarelli FR; Baldi C; Massimino M; Sanson M; Giangaspero F
Pediatr Blood Cancer; 2015 Apr; 62(4):724-7. PubMed ID: 25382612
[TBL] [Abstract][Full Text] [Related]
17. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
18. Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases.
Upadhyaya SA; Robinson GW; Harreld JH; Klimo PD; Hoehn ME; Orr BA; Qaddoumi IA
Childs Nerv Syst; 2018 Apr; 34(4):605-610. PubMed ID: 29392423
[TBL] [Abstract][Full Text] [Related]
19. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.
Romano E; Pradervand S; Paillusson A; Weber J; Harshman K; Muehlethaler K; Speiser D; Peters S; Rimoldi D; Michielin O
Clin Cancer Res; 2013 Oct; 19(20):5749-57. PubMed ID: 23948972
[TBL] [Abstract][Full Text] [Related]
20. Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups.
Kurani H; Gurav M; Shetty O; Chinnaswamy G; Moiyadi A; Gupta T; Jalali R; Epari S
Childs Nerv Syst; 2019 Sep; 35(9):1525-1536. PubMed ID: 31321520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]